ERYTHRODERMIC PSORIASIS
Clinical trials for ERYTHRODERMIC PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new ERYTHRODERMIC PSORIASIS trials appear
Sign up with your email to follow new studies for ERYTHRODERMIC PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare, severe psoriasis flares
Disease control OngoingThis study tests an oral medication, JNJ-77242113, in 19 adults with two rare and severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The goal is to see if the drug can control symptoms like widespread redness, pustules, and swelling.…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated May 17, 2026 07:37 UTC
-
New drug shows promise for rare, severe psoriasis
Disease control OngoingThis study tests whether TAK-279 can improve symptoms of two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. About 18 adults will receive the drug for up to 52 weeks. The main goal is to see if their skin becomes clear or almost cle…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 07:35 UTC